Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-Label Extension Study of Vosoritide in Children with Achondroplasia
2017-002404-28Phase 3Unknown
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Change from baseline in annualized growth velocity. Status: unknown.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2017-002404-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002404-28.